Alnylam Q3 2023 net product revenues $313M (+35% YoY); FDA CRL for ONPATTRO cardiomyopathy

ALNYLAM PHARMACEUTICALS, INC.

2023-Q3 EPS reported -$2.43 revenue$1,388,574,000

Q3 net product revs $313M (+35% YoY); GAAP net income $147.8M ($1.15 diluted EPS) vs loss of $405.9M in Q3 2022.
FDA issued Complete Response Letter for patisiran (ONPATTRO) sNDA for ATTR cardiomyopathy.
Positive topline results from KARDIA-1 Phase 2 study of zilebesiran in hypertension; entered global collaboration with Roche.
Updated 2023 guidance: collaboration & royalty rev $575-625M; net product rev reiterated at $1,200-1,285M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ALNYLAM PHARMACEUTICALS, INC. reported third quarter ended September 30, 2023 results: revenue $313 Million, net income $147,753, EPS $1.18.

Period: third quarter ended September 30, 2023
Revenue: $313 Million
Net income: $147,753
EPS: $1.18
Result: reported results

Exact text from the filing

Alnylam Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Period Activity − Achieved Third Quarter 2023 Global Net Product Revenues of $313 Million, Representing 35% Year-Over-Year Growth Compared to Q3 2022 –

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

ALNYLAM PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001157523-23-001622

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.